Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Anisole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.50 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.48 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.48 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 2/20 | 0.93 |
| ▸ | LTA4H | P09960 | 3/20 | 0.74 |
| ▸ | CA1 | P00915 | 3/20 | 0.62 |
| ▸ | CA2 | P00918 | 3/20 | 0.62 |
| ▸ | CA7 | P43166 | 3/20 | 0.62 |
| ▸ | CA9 | Q16790 | 3/20 | 0.62 |
| ▸ | CA12 | O43570 | 2/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.62 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anisole SCHEMBL3840007 | 1.00 | — | — | |
| Anisole SCHEMBL2493788 | 0.97 | CA4 (1.00) | CA4LTA4HCA1CA2CA7 | |
| Anisole SCHEMBL1205 | 0.97 | — | — | |
| Anisole SCHEMBL27342302 | 0.97 | CA4 (1.00) | CA4LTA4HCA1CA2CA7 | |
| Anisole SCHEMBL8472521 | 0.97 | CA4 (1.00) | CA4LTA4HCA1CA2CA7 | |
| Anisole SCHEMBL10721106 | 0.97 | CA4 (1.00) | CA4LTA4HCA1CA2CA7 | |
| Anisole SCHEMBL20328417 | 0.97 | — | — | |
| Anisole SCHEMBL28813915 | 0.97 | CA4 (1.00) | CA4LTA4HCA1CA2CA7 | |
| Anisole SCHEMBL30601749 | 0.97 | — | — | |
| Anisole SCHEMBL5377903 | 0.93 | CA4 (0.93) | CA4LTA4HCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339975-A1 | CRYSTALLINE FORM OF SHP2 INHIBITOR, AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| EP-4169920-A1 | CRYSTALLINE FORM OF SHP2 INHIBITOR, AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2023-04-26 | — | — | EP | disclosed |
| CN-108701657-B | Curable resin composition and fan-out type wafer level package | 太阳油墨制造株式会社 | 2022-05-13 | — | — | CN | disclosed |
| CN-109836444-B | Preparation method of lithium difluoroborate | 东莞东阳光科研发有限公司 | 2021-05-11 | — | — | CN | disclosed |
| CN-110819263-A | Back grinding belt | 日东电工株式会社 | 2020-02-21 | — | — | CN | disclosed |
| CN-110819249-A | Back grinding belt | 日东电工株式会社 | 2020-02-21 | — | — | CN | disclosed |
| CN-110072696-A | Touch sensor assemblies and planarization band | 3M创新有限公司 | 2019-07-30 | — | — | CN | disclosed |
| CN-108701657-A | The wafer-class encapsulation of curable resin constituent and fan-out-type | 太阳油墨制造株式会社 | 2018-10-23 | — | — | CN | disclosed |
| US-7288557-B2 | For preventing or treating proliferative diseases and conditions such as cancer; eg 4-[1,2,3]Triazol-1-yl-1-(4-{2-[(E)-2-(4-trifluoromethoxy-phenyl)-vinyl]-oxazol-4-ylmethoxy}-phenyl)-butan-1-one | HOFFMANN-LA ROCHE INC. (US) | 2007-10-30 | — | — | US | disclosed |
| EP-1794153-A1 | 1,2,3-TRIAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| US-20060211750-A1 | Triazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | US | disclosed |
| WO-2006032453-A1 | 1,2,3 -TRIAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-03-30 | — | — | WO | disclosed |
| CN-1688345-A | Composition having stabilized redox properties and method of stabilizing redox properties | VARDOSANIDZE IRINA VIKTOROVNA (RU) | 2005-10-26 | — | — | CN | disclosed |
| US-4675454-A | SULFATED OXIDE OF COPPER, SILVER OR GOLD AS ETHERIFICATION CATALYST | AMOCO CORPORATION (US) | 1987-06-23 | — | — | US | disclosed |
| US-4675455-A | SULFATED OXIDE OF GROUP 6 METAL CATALYST | AMOCO CORPORATION (US) | 1987-06-23 | — | — | US | disclosed |
| US-4675456-A | USING SULFATED OXIDE OF LANTHANIDE SERIES; CATALYST ON SUPPORT | AMOCO CORPORATION (US) | 1987-06-23 | — | — | US | disclosed |
| US-4638098-A | GROUP II B METAL SULFATE CATALYSTS | AMOCO CORPORATION (US) | 1987-01-20 | — | — | US | disclosed |
| US-4611084-A | Catalytic etherification of phenols to alkyl aryl ethers | AMOCO CORPORATION (US) | 1986-09-09 | — | — | US | disclosed |
| US-4124750-A | DIENE POLYMER CROSSLINKED WITH A DIHYDRAZIDE COMPOUND | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 1978-11-07 | — | — | US | disclosed |
| US-4103077-A | Green strength of synthetic elastomers | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 1978-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211750-A1 | Triazole derivatives | CYP3A43, CYP3A5, CYP11B2 | ACHE 3332/4885DRD2 3270/4885DRD4 3057/4885 |
| US-20230339975-A1 | CRYSTALLINE FORM OF SHP2 INHIBITOR, AND COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | PTPN1, PTPN11, PTPN7 | ACHE 4669/4885DRD2 4789/4885DRD4 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.